Helicobacter pylori infection reduces cancer immunotherapy efficacy through hepatic urea cycle activation and creatine depletion
Open Access
- 16 October 2026
- journal article
- Published by BMJ in Gut Science
- Vol. 1 (1) , e000039
Abstract
Background Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients. Increasing evidence implicates the gut microbiota in modulating ICI responses. We previously identified Helicobacter pylori infection as a negative predictor of ICI efficacy.Objective Here, we aimed to elucidate the metabolic mechanisms by which H. pylori impairs antitumour immunity and to evaluate creatine supplementation as a potential therapeutic intervention.Design Using murine models of neonatal H. pylori infection and cancer immunotherapy, we conducted targeted plasma metabolomics, hepatic gene and protein expression profiling and isotope tracing to delineate infection-induced metabolic alterations. Functional assays were used to assess the impact of creatine on CD8+ T cell activation in vitro and in vivo, including CRISPR-Cas9-mediated knockdown of the creatine transporter Slc6a8.Results Neonatal H. pylori infection accelerated the hepatic urea cycle, resulting in systemic depletion of creatine and its precursors. Creatine supplementation restored antitumour immunity in infected mice in a CD8+ T cell-dependent manner. Mechanistically, creatine increased the frequency of tumour-specific effector and effector memory CD8+ T cells in tumour-draining lymph nodes and enhanced the population of tumour-infiltrating T cell factor-1⁻ (TCF-1) granzyme B+ effector CD8+ T cells.Conclusion H. pylori drives metabolic reprogramming that undermines ICI efficacy through creatine depletion and CD8+ T cell dysfunction. Creatine supplementation may offer a promising adjuvant approach to overcome H. pylori-associated resistance to cancer immunotherapy.Keywords
Funding Information
- German Cancer Aid
- European Research Council (Starting grant (SOAR))
- Swiss Cancer Research Foundation (KFS-5631-08-2022-R)
This publication has 70 references indexed in Scilit:
- Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunityCell, 2025
- SLC6A8-mediated creatine uptake suppresses ERK2-FSP1 signaling and induces ferroptosis in colorectal cancerCell Reports, 2025
- Down the road towards hepatic encephalopathy. Urea synthesis - the liver workhorse of nitrogen metabolismMetabolic Brain Disease, 2024
- Creatine transport and creatine kinase activity is required for CD8+ T cell immunityCell Reports, 2022
- Tumour‐derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8‐mediated creatine import in NPM1‐mutated acute myeloid leukaemiaJournal of Extracellular Vesicles, 2021
- Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell FunctionImmunity, 2019
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade ImmunotherapyImmunity, 2019
- Resolution and evaluation of 3-chlorophenyl-3-hydroxypropionylhydroxamic acid as antivirulence agent with excellent eradication efficacy in Helicobacter pylori infected miceEuropean Journal of Pharmaceutical Sciences, 2018
- PD-1 blockade in advanced NSCLC: A focus on pembrolizumabCancer Treatment Reviews, 2018
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor ActivityCell, 2016